Artivion (NYSE:AORT) CEO James Mackin Sells 17,887 Shares of Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 17,887 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $675,770.86. Following the sale, the chief executive officer owned 947,275 shares in the company, valued at approximately $35,788,049.50. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Artivion Stock Down 0.5%

Shares of NYSE:AORT opened at $38.41 on Thursday. The firm has a market capitalization of $1.84 billion, a PE ratio of 192.06 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The firm has a fifty day moving average of $41.42 and a 200 day moving average of $42.92.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Management will deliver a virtual fireside chat at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference — a chance to update guidance, commercialization progress or product milestones that could re‑ignite institutional interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutions have been increasing exposure (notably Invesco’s sizable Q4 add), which can provide steadier bid support and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Positive Sentiment: Analyst coverage remains constructive: consensus is a “Moderate Buy” with several buy/outperform ratings and mid‑to‑high price targets that underpin demand at current levels. MarketBeat – Analyst Ratings
• Neutral Sentiment: Last reported quarter (Feb. 12) beat EPS and revenue estimates and showed ~19% YoY revenue growth — supports the growth story but may be at least partially priced in. MarketBeat – Artivion Earnings Summary
• Neutral Sentiment: Recent media pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite, which help the narrative but are not hard catalysts by themselves. Portfolio Expansion Article
• Negative Sentiment: Multiple senior insiders (including CEO James Mackin, EVP Lance Berry, several SVPs and the CAO) sold shares on March 2–4 in a concentrated wave of Form 4 filings — markets often view clustered insider selling as a near‑term negative even though insiders retain large stakes. Monitor whether sales continue or were pre‑planned/for tax/liquidity reasons. Insider Trades Alert (March 4)

Analyst Ratings Changes

Several research analysts have commented on AORT shares. Oppenheimer reissued an “outperform” rating and set a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citizens Jmp boosted their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Canaccord Genuity Group decreased their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $48.97.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after acquiring an additional 141,030 shares in the last quarter. Morgan Stanley boosted its stake in shares of Artivion by 0.8% during the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after purchasing an additional 18,248 shares in the last quarter. State Street Corp increased its position in shares of Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after buying an additional 44,641 shares during the period. Fred Alger Management LLC raised its stake in Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after buying an additional 55,322 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after buying an additional 748,119 shares during the period. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.